2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
476
Carcinoma, Non-Small-Cell Lung
233
Breast Neoplasms
196
Ovarian Neoplasms
171
Glioblastoma
157
Carcinoma, Hepatocellular
131
Neoplasms
128
Rectal Neoplasms
114
Colonic Neoplasms
110
Neoplasm Metastasis
106
Brain Neoplasms
98
Lung Neoplasms
96
Fallopian Tube Neoplasms
85
Carcinoma, Renal Cell
77
Glioma
69
Pancreatic Neoplasms
54
Liver Neoplasms
44
Melanoma
43
Gliosarcoma
43
Uterine Cervical Neoplasms
40
Adenocarcinoma of Lung
39
Stomach Neoplasms
37
Recurrence
33
Astrocytoma
30
Carcinoma, Ovarian Epithelial
28
Endometrial Neoplasms
27
Triple Negative Breast Neoplasms
26
Kidney Neoplasms
23
Prostatic Neoplasms
22
Esophageal Neoplasms
21
Interventions
Glucose Tolerance Test
2
penclomedine
1
atezolizumab
1
Triptorelin Pamoate
1
Tomography, X-Ray Computed
1
Proton Magnetic Resonance Spectroscopy
1
Pancreaticoduodenectomy
1
Orchiectomy
1
Olive Oil
1
Metformin
1
Liquid Biopsy
1
Exenatide
1
Excitatory Amino Acids
1
Endosonography
1
Diet, Ketogenic
1
Blood Specimen Collection
1
Bevacizumab
1
Amino Acids, Essential
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fatty Liver
×
Bevacizumab
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled